Does Aetna Cover Weight Loss Treatment in Hawaii? A 2026 Guide

Last updated: July 17, 2026

Key update for Aetna members in Hawaii: Zepbound (tirzepatide) has been reinstated on CVS Caremark commercial formularies effective October 1, 2026. Aetna uses CVS Caremark as its pharmacy benefits manager (PBM) in Hawaii. If your Zepbound request was previously denied due to formulary removal, you may be eligible to resubmit a prior authorization (PA) after October 1, 2026. Wegovy (semaglutide) remains available on the CVS Caremark formulary with PA required. GLP-1 medications for weight loss typically require prior authorization demonstrating a BMI of 30 or higher (or 27+ with a qualifying weight-related condition).

Hawaii Electronic Prescribing of Controlled Substances (EPCS): All weight loss medications — GLP-1s, Contrave, and orlistat — are non-scheduled. Phentermine and Qsymia are Schedule IV, which is NOT subject to Hawaii EPCS under HRS § 329-38.5 (Schedule II only). No weight loss medication commonly prescribed for obesity treatment requires electronic prescribing under Hawaii state law.

See if your Aetna plan may cover weight loss treatment through Klarity →

Does Aetna Cover Weight Loss Treatment in Hawaii?

Aetna may cover a range of weight loss treatments for eligible members in Hawaii, including prescription GLP-1 medications, obesity counseling, and medically supervised weight management programs. Coverage depends on your specific Aetna plan, your employer’s benefit design, and whether the treatment meets Aetna’s medical necessity criteria.

Aetna administers pharmacy benefits in Hawaii through CVS Caremark, one of the largest pharmacy benefit managers in the United States. This means that formulary coverage for prescription weight loss medications — including Wegovy, Zepbound, Saxenda, Contrave, orlistat, and phentermine — follows CVS Caremark’s standard commercial formulary tiers.

This guide explains what Aetna members in Hawaii may expect from their plan, how prior authorization works, and what the recent Zepbound reinstatement on CVS Caremark means for your treatment options.

CVS Caremark Weight Loss Formulary for Aetna Hawaii Members (2026)

Aetna uses CVS Caremark as its PBM in Hawaii. The following table reflects the CVS Caremark standard commercial formulary for weight loss medications. Your specific plan may vary — always verify your benefits by calling the member services number on your Aetna ID card or using the CVS Caremark drug lookup tool at caremark.com.

Coverage varies by plan. Self-funded employer plans administered by Aetna may exclude weight loss medications entirely. Verify your specific benefits before starting treatment.

Prior Authorization for Weight Loss Medications Under Aetna Hawaii

Most prescription weight loss medications under Aetna’s CVS Caremark formulary in Hawaii require prior authorization. Your prescribing provider submits the PA request on your behalf; you do not need to submit it yourself.

Typical PA Criteria for GLP-1 Weight Loss Medications

• BMI of 30 or higher; or BMI of 27 or higher with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• FDA-approved weight loss indication (Wegovy or Zepbound, not Ozempic or Mounjaro)
• Documentation of lifestyle intervention or dietary counseling
• Step therapy may be required on some plans: trial of an oral agent (Contrave or orlistat) before a GLP-1 is approved
• Annual reauthorization, typically requiring documentation of at least 5% body weight reduction at 16 weeks

How to Submit a Prior Authorization Request to Aetna

• Provider portal: Availity (availity.com) — the primary PA submission channel for Aetna
• Aetna provider portal: aetna.com/providers
• Phone: Aetna member services 1-800-872-3862; CVS Caremark member line 1-800-552-8159
• Standard processing time: 2–3 business days (non-urgent); urgent requests 24–72 hours

If your PA request is denied, you have the right to appeal. Ask your provider to submit a clinical appeal with supporting documentation, including BMI records, comorbidity diagnoses, and evidence of prior treatment attempts.

Zepbound Reinstated on Aetna/CVS Caremark Plans — October 1, 2026

CVS Caremark announced on May 28, 2026 that Zepbound (tirzepatide, Eli Lilly) would be reinstated on its commercial formularies effective October 1, 2026. Since Aetna uses CVS Caremark as its PBM in Hawaii, this reinstatement applies to Aetna commercial members statewide.

What this means for Aetna Hawaii members:

• Zepbound is expected to return to Tier 3–4 coverage with prior authorization on most CVS Caremark commercial formularies starting October 1, 2026
• Members who had Zepbound denied before the reinstatement should work with their provider to resubmit a PA request after October 1, 2026
• Wegovy (semaglutide, Novo Nordisk) remains available on the CVS Caremark formulary and continues to be the primary GLP-1 alternative in the interim period

Important distinction: Cigna members in Hawaii use Express Scripts (ESI) as their PBM. ESI never removed Zepbound from its commercial formulary — Zepbound has remained available at Tier 3–4 on ESI plans throughout 2025–2026. The October 1, 2026 reinstatement language applies specifically to CVS Caremark plans (Aetna, HMSA), not to Cigna/ESI plans.

Medicare GLP-1 Bridge (excluded): The CMS Medicare GLP-1 Bridge, launched July 1, 2026, offers Wegovy, Zepbound, and Foundayo at $50/month for eligible Medicare Advantage MAPD members. This program does not apply to Aetna commercial plans in Hawaii — it is a Medicare Advantage benefit only. Aetna commercial members should not expect $50/month pricing through this program.

Hawaii EPCS and Weight Loss Medications

Hawaii’s Electronic Prescribing of Controlled Substances (EPCS) law is codified at HRS § 329-38.5 and applies to Schedule II controlled substances only.

For weight loss medications:

• GLP-1 medications (Wegovy, Zepbound, Saxenda): Non-scheduled (not controlled substances) — HRS § 329-38.5 is entirely inapplicable
• Contrave (naltrexone/bupropion): Non-scheduled — EPCS inapplicable
• Orlistat: Non-scheduled — EPCS inapplicable
• Phentermine: Schedule IV controlled substance — NOT subject to HRS § 329-38.5 (Schedule II only); can be prescribed via standard electronic or paper prescription in Hawaii
• Qsymia (phentermine/topiramate): Schedule IV — NOT subject to HRS § 329-38.5. Note: Qsymia has a separate FDA REMS (Risk Evaluation and Mitigation Strategy) requiring prescriber certification — this is a federal FDA requirement, not a Hawaii state EPCS requirement

Bottom line: No weight loss medication in standard clinical use for obesity treatment requires electronic prescribing under Hawaii law. This contrasts with states such as West Virginia, where W. Va. Code § 60A-4-403a applies EPCS to all controlled substances, including Schedule IV phentermine. Hawaii’s Schedule II-only scope means HI providers and patients face no EPCS barriers for any weight loss prescription.

Hawaii Mental Health Parity Law and Weight Loss Coverage

Hawaii’s mental health parity law — Haw. Rev. Stat. § 431M-1 et seq. — requires that state-regulated commercial insurance plans provide mental health and substance use disorder (MH/SUD) benefits on par with medical and surgical benefits. This law does not govern weight loss treatment coverage.

Weight loss medication coverage for Aetna members in Hawaii is instead governed by:

• ACA Essential Health Benefits (EHB): Individual and small-group plans sold through Hawaii’s health insurance marketplace must cover EHBs. Weight loss medications are not currently a required EHB category, though preventive obesity counseling may be covered without cost-sharing under ACA preventive care mandates
• Plan design and employer benefit decisions: Large employer (ERISA) plans have flexibility to exclude or include weight loss drug coverage at the employer’s discretion
• ERISA carve-out: Self-funded employer plans administered by Aetna are governed by federal ERISA law, not Hawaii state insurance statutes. These plans may have different — or more restrictive — weight loss coverage than fully insured Aetna plans regulated by the Hawaii Insurance Division

Hawaii Prepaid Health Care Act and Weight Loss

Hawaii’s Prepaid Health Care Act (HRS § 393) requires employers with employees working 20 or more hours per week to provide health insurance coverage. This makes Hawaii one of the few states with an employer health coverage mandate predating the ACA.

However, the Prepaid Health Care Act does not mandate coverage for specific medications, including weight loss drugs. Whether a plan covers Wegovy, Zepbound, or other weight loss prescriptions remains a plan design decision — governed by the employer’s benefit structure, ACA EHB requirements, and Aetna’s group plan terms.

Questions about Hawaii’s employer health coverage requirements can be directed to the Hawaii Department of Labor and Industrial Relations (DLIR) at 1-808-586-8777.

What Weight Loss Services May Be Covered by Aetna in Hawaii?

Beyond prescription medications, Aetna plans in Hawaii may cover a range of weight management services, depending on your specific plan:

• Preventive obesity counseling: ACA-mandated for adults with BMI ≥30, typically with no cost-sharing on qualifying plans
• Medical weight management evaluation: Office visits with a primary care provider or obesity medicine specialist
• Telehealth weight management: Virtual consultations with licensed providers, including prescription management for weight loss medications
• Nutritional counseling and dietitian services: Often covered with referral; varies by plan
• Behavioral health weight management programs: May be covered as MH/SUD benefit on plans subject to § 431M-1
• Bariatric surgery: Coverage varies significantly; typically requires extensive pre-authorization documentation, supervised weight loss attempts, and psychological evaluation
• Prescription weight loss medications: As detailed in the formulary table above, subject to PA and medical necessity criteria

How to Verify Your Aetna Weight Loss Coverage in Hawaii

1. Call Aetna member services: 1-800-872-3862 (number on your ID card); ask specifically about weight loss medication coverage, PA requirements, and formulary tier for the medication your provider recommends
2. Check the CVS Caremark drug lookup tool: Visit caremark.com and search for your medication using your plan information to confirm current formulary status and tier
3. Review your Summary of Benefits and Coverage (SBC): Available through your employer’s HR portal or by calling Aetna; review the pharmacy and outpatient benefits sections
4. Talk with your provider: A licensed provider can verify PA requirements and submit the prior authorization on your behalf through Availity or aetna.com/providers
5. Contact the Hawaii Insurance Division: If you have a coverage dispute or denial you believe was wrongful, contact the Hawaii Insurance Division at 1-808-586-2790 or insurance.hawaii.gov

Check if your Aetna plan may cover weight loss treatment through Klarity →

Get Weight Loss Treatment Through Klarity Health

Klarity Health connects patients in Hawaii with licensed providers who may prescribe FDA-approved weight loss medications, including GLP-1 agonists, through telehealth. Our network of 2,000+ licensed providers includes physicians and nurse practitioners experienced in obesity medicine and metabolic health.

Klarity providers can:

• Evaluate your eligibility for prescription weight loss medications
• Submit prior authorization requests to Aetna on your behalf
• Coordinate with CVS Caremark for pharmacy fulfillment
• Provide ongoing medication management and follow-up via telehealth

See if you may qualify for weight loss treatment — verify your Aetna benefits →

Key Contacts for Aetna Weight Loss Coverage in Hawaii

• Aetna Member Services: 1-800-872-3862
• CVS Caremark Member Line: 1-800-552-8159
• Aetna Prior Authorization (Provider): Availity (availity.com) / aetna.com/providers
• Hawaii Insurance Division: 1-808-586-2790 / insurance.hawaii.gov
• Hawaii Department of Labor and Industrial Relations (DLIR): 1-808-586-8777
• CMS Medicare (GLP-1 Bridge — MA members only): 1-800-633-4227
• SAMHSA National Helpline: 1-800-662-4357
• 988 Suicide & Crisis Lifeline: 988

Frequently Asked Questions

Does Aetna cover Wegovy for weight loss in Hawaii?

Wegovy (semaglutide) may be covered under Aetna plans in Hawaii that use CVS Caremark. Coverage typically requires prior authorization, a BMI of 30 or higher (or 27+ with a weight-related condition), and documentation that the FDA-approved weight loss indication (not the diabetes indication) is being treated. Coverage varies by plan — verify your specific benefits by calling Aetna at 1-800-872-3862.

Is Zepbound covered by Aetna in Hawaii after the October 2026 reinstatement?

Zepbound (tirzepatide) is expected to be reinstated on CVS Caremark commercial formularies effective October 1, 2026. Since Aetna uses CVS Caremark in Hawaii, Aetna Hawaii commercial members may have Zepbound coverage restored after that date, subject to prior authorization and medical necessity criteria. Members whose Zepbound PA was denied before the reinstatement should work with their provider to resubmit after October 1, 2026.

Does phentermine require electronic prescribing in Hawaii?

No. Hawaii’s EPCS law (HRS § 329-38.5) applies to Schedule II controlled substances only. Phentermine is a Schedule IV controlled substance and is NOT subject to the Hawaii EPCS requirement. Similarly, Qsymia (phentermine/topiramate), also Schedule IV, is not subject to HRS § 329-38.5 — though Qsymia does carry a separate federal FDA REMS prescriber certification requirement unrelated to state EPCS law.

Does Hawaii’s parity law require Aetna to cover weight loss medications?

No. Hawaii’s mental health parity law (Haw. Rev. Stat. § 431M-1 et seq.) governs mental health and substance use disorder treatment parity only. It does not require coverage of weight loss medications. Weight loss drug coverage depends on ACA Essential Health Benefits rules (for individual/small-group plans) and employer benefit design decisions (for large-group and self-funded ERISA plans).

What is the Medicare GLP-1 Bridge, and does it apply to my Aetna plan?

The Medicare GLP-1 Bridge, launched July 1, 2026, allows eligible Medicare Advantage MAPD members to access Wegovy, Zepbound, and Foundayo at approximately $50/month through CMS. This program applies to Medicare Advantage members only — it does not apply to Aetna commercial plans in Hawaii. If you have Aetna commercial insurance (employer or individual market), the Medicare GLP-1 Bridge pricing is not available to you.

What can I do if Aetna denies my prior authorization for a weight loss medication?

If Aetna denies your PA request, you have the right to appeal. Your provider can submit a clinical appeal with supporting documentation — BMI records, comorbidity diagnoses, treatment history, and clinical notes supporting medical necessity. If the internal appeal is denied, you may request an external review through the Hawaii Insurance Division (1-808-586-2790). Hawaii law generally requires insurers to process standard appeals within 30 days and expedited appeals within 72 hours.

Disclaimer: This article is for informational purposes only and does not constitute insurance, legal, or medical advice. Coverage information reflects general knowledge of Aetna and CVS Caremark policies as of July 2026 and may not reflect your specific plan’s terms. Coverage varies by plan, employer benefit design, and individual medical necessity determinations. Always verify your benefits directly with Aetna before beginning treatment. Klarity Health is not affiliated with Aetna or CVS Caremark.